Compare ING Groep NV (ING) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? ING Groep NV trades at $33.42 (market cap $94.92B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: ING Groep NV is far larger — about 97.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and ING Groep NV pays a 3.93% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ING | MRVI | |
|---|---|---|
Market Cap | $94.92B | $972.90M |
Volume | 2,055,666 | 4,325,710 |
Sector | Financials | Health |
52-Week High | $37.27 | $9.00 |
52-Week Low | $23.66 | $2.83 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $237.77B | $1.08B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.46, up 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.75 estimate. Revenue reached $22.90 billion in 2025, with a net income margin of 28.34%. Analyst sentiment is positive, with 11 buy ratings and no sell ratings among 17 analysts. Recent news highlights an upgraded ROE target above 16% for 2027 and strategic focus on organic growth.
The outlook for ING is cautiously optimistic, supported by earnings momentum and favorable analyst coverage. Key opportunities include revenue growth and profitability targets, while risks involve persistent negative operating cash flows and regulatory scrutiny, such as recent capital requirements in Australia. The stock's valuation metrics, including a P/E of 12.99, suggest reasonable pricing relative to earnings.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
